Clinical Reviews in Allergy & Immunology

, Volume 31, Issue 2–3, pp 259–268 | Cite as

β2-Agonists at the olympic games

  • Kenneth D. Fitch


The different approaches that the International Olympic Committee (IOC) had adopted to β2-agonists and the implications for athletes are reviewed by a former Olympic team physician who later became a member of the Medical Commission of the IOC (IOC-MC). Steadily increasing knowledge of the effects of inhaled β2-agonists on health, is concerned with the fact that oral β2-agonists may be anabolic, and rapid increased use of inhaled β2-agonists by elite athletes has contributed to the changes to the IOC rules. Since 2001, the necessity for athletes to meet IOC criteria (i.e., that they have asthma and/or exercise-induced asthma [EIA]) has resulted in imporved management of athletes. The prevalence of β2-agonist use by athletes mirrors the known prevalence of asthma symptoms in each country, although athletes in endurance events have the highest prevalence. The age-of-onset of asthma/EIA in elite winter athletes may be atypical. Of the 193 athletes at the 2006 Winter Olympics who met th IOC's criteria, only 32.1% had childhood asthma and 48.7% of athletes reported onset at age 20 yr or older. These findings lead to speculation that years of intense endurance training may be a causative factor in bronchial hyperreactivity. The distinction between oral (prohibited in sports) and inhaled salbutamol is possible, but athletes must be warned that excessive use of inhaled salbutamol can lead to urinary concentrations similar to those observed after oral administration. This article provides justification that athletes should provide evidence of asthma or EIA before being permitted to use inhaled β2-agonists.

Index Entries

Asthma β2-agonists Olympics doping performance 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Crane, J., Pearce, N., Flatt, A., et al. (1989), Prescribed fenoterol and death from asthma in New Zealand, 1981–83: case-control study. Lancet 1, 917–922.PubMedCrossRefGoogle Scholar
  2. 2.
    Clausnitzer, C. (1985), Communication to IOC Medical Commission 18 March.Google Scholar
  3. 3.
    Fitch, K. D. (1986), The use of anti-asthmatic drugs. Do they affect sports performance? Sports Med. 3, 136–150.PubMedGoogle Scholar
  4. 4.
    Phillips, W. N. (1992). The secret of clenbuterol. Special Report #1. Golden, CO: Mile High Publishing.Google Scholar
  5. 5.
    Martineau, L., Horan, M. A., Rothwell, N. J., and Little, R. A. (1992), Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin. Sci. (Lond.), 83, 615–621.CrossRefGoogle Scholar
  6. 6.
    Larsson, K., Ohlsen, P., Larsson, L., Malmberg, P., Rydstrom, P. O., and Ulriksen, H. (1993), High prevalence of asthma in cross country skiers. BMJ 307, 1326–1329.PubMedGoogle Scholar
  7. 7. index_uk.asp, Accessed January 14, 2006.Google Scholar
  8. 8.
    Anderson, S. D., Fitch, K., Perry, C. P., et al. (2003), Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J. Allergy Clin. Immunol. 111, 45–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Anderson, S. D., Sue-Chu, M., Perry, C. P., et al. (2006), Bronchial challenges in athletes applying to inhale a β2-agonist at the 2004 summer Olympics. J. Allergy Clin. Immunol. 117, 767–773.PubMedCrossRefGoogle Scholar
  10. 10.
    Hancox, R. J., Subbarao, P., Kamada, D., Watson, R. M., Hargreave, F. E., and Inman, M. D. (2002), Beta2-agonist tolerance and exercise-induced bronchospasm. Am. J. Respir. Crit. Care Med. 165, 1068–1070.PubMedGoogle Scholar
  11. 11.
    Ramage, L., Lipworth, B. J., Ingram, C. G., Cree, I. A., and Dhillon, D. P. (1994), Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. 88, 363–368.PubMedCrossRefGoogle Scholar
  12. 12.
    Storms, W., Chervinsky, P., Ghannam, A. F., Bird, S., Hustad, C. M., and Edelman, J. M. (2004), A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med. 98, 1051–1062.PubMedCrossRefGoogle Scholar
  13. 13.
    Anderson, S. D. and Brannan, J. D. (2004) Longacting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future. Paediatr. Drugs 6, 161–175.PubMedCrossRefGoogle Scholar
  14. 14.
    Haney, S. and Hancox, R. J. (2005), Rapid onset of tolerance to beta-agonist bronchodilation. Respir. Med. 99, 566–571.PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson, S. D., Brusasco, V., Haahtela, T., and Popov, T. (2005), Criteria for diagnosis of asthma, exercise-induced bronchoconstriction and airway hyperesponsiveness for athlete: Lessons from the Olympic Games. In Diagnosis, Prevention and Treatment of Exercise Related Asthma, Respiratory and Allergic Disorders in Sports, Carlsen, K.-H., Delgado, L., and Del Giacco, S., eds., Eur Respir Mon. Wakefield, UK: European Respiratory Society, pp. 48–66.Google Scholar
  16. 16.
    Dickinson, J. W., Whyte, G. P., McConnell, A. K., and Harries, M. G. (2005), Impact of changes in the IOC-MC asthma criteria: a British perspective. Thorax 60, 629–632.PubMedCrossRefGoogle Scholar
  17. 17.
    Bjermer, J. and Anderson, S. D. (2005), Bronchial hyperresponsiveness in athletes; mechanisms for development. In Diagnosis, Prevention and Treatment of Exercise Related Asthma, Respiratory and Allergic Disorders in Sports, Carlsen, K.-H., Delgado, L., and Del Giacco, S., eds., Eur Respir Mon Wakefield UK: European Respiratory Society, pp. 19–34.Google Scholar
  18. 18.
    Fitch, K. D., Morton, A. R., and Blanksby, B. A. (1976), Effects of swimming training on children with asthma. Arch. Dis. Child. 51, 19–194.Google Scholar
  19. 19.
    Drobnic, F. and Haahtela, T. (2005), The role of the environment and climate in relation to outdoor and indoor sports. In Diagnosis, Prevention and Treatment of Exercise Related Asthma, Respiratory and Allergic Disorders in Sports, Carlsen, K.-H., Delgado, L., and Del Giacco, S., eds., Eur Respir Mon. Wakefield, UK: European Respiratory Society, pp. 35–47.Google Scholar
  20. 20.
    (1998), Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 351, 1225–1232.Google Scholar
  21. 21.
    Chinn, S., Burney, P., Jarvis, D., and Luczynska, C. (1997), Variation in bronchial responsiveness in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. J. 10, 2495–2501.PubMedCrossRefGoogle Scholar
  22. 22.
    Fitch, K. D. (1984), Management of allergic Olympic athletes. J. Allergy Clin. Immunol. 73, 722–727.PubMedCrossRefGoogle Scholar
  23. 23.
    Delbeke, F. T., Desmet, N., and Debackere, M. (1995), The abuse of doping agents in competing body builders in Flanders (1988–1993). Int. J. Sports Med. 16, 66–70.PubMedGoogle Scholar
  24. 24.
    Yang, Y. T. and McElligott, M. A. (1989), Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem. J. 261, 1–10.PubMedGoogle Scholar
  25. 25.
    McKenzie, D. C., Rhodes, E. C., Stirling, D. R., et al. (1983), Salbutamol and treadmill performance in non-atopic athletes. Med. Sci. Sports Exerc. 15, 520–522.PubMedGoogle Scholar
  26. 26.
    Meeuwisse, W. H., McKenzie, D. C., Hopkins, S. R., and Road, J. D. (1992), The effect of salbutamol on performance in elite nonasthmatic athletes. Med. Sci. Sports Exerc. 24, 1161–1166.PubMedGoogle Scholar
  27. 27.
    Morton, A. R., Papalia, S. M., and Fitch, K. D. (1992), Is salbutamol ergogenic? The effects of salbutamol on physical performance in high performance nonasthmatic athletes. Clin. J Sport Med. 2, 93–97.CrossRefGoogle Scholar
  28. 28.
    Heir, T. and Stemshaug, H. (1995), Salbutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes. Scand. J. Med. Sci. Sports 5, 231–236.PubMedCrossRefGoogle Scholar
  29. 29.
    Morton, A. R., Joyce, K., Papalia, S. M., Carroll, N. G., and Fitch, K. D. (1996), Is salmeterol ergogenic? Clin. J. Sport Med. 6, 220–225.PubMedCrossRefGoogle Scholar
  30. 30.
    Sue-Chu, M., Sandsund, M., Helgerud, J., Reinertsen, R. E., and Bjermer, L. (1999), Salmeterol and physical performance at −15 degrees C in highly trained nonasthmatic cross-country skiers. Scand. J. Med. Sci. Sports 9, 48–52.PubMedCrossRefGoogle Scholar
  31. 31.
    Carlsen, K. H., Hem, E., Stensrud, T., Held, T., Herland, K., and Mowinckel, P. (2001), Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes. Respir. Med. 95, 571–576.PubMedCrossRefGoogle Scholar
  32. 32.
    Stewart, I. B., Labreche, J. M., and McKenzie, D. C. (2002), Acute formoterol administration has no ergogenic effect in nonasthmatic athletes. Med. Sci. Sports Exerc. 34, 213–217.PubMedCrossRefGoogle Scholar
  33. 33.
    Larsson, K., Gavhed, D., Larsson, L., Holmer, I., Jorfelt, L., and Ohlsen, P. (1997), Influence of a beta2-agonist on physical performance at low temperature in elite athletes. Med. Sci. Sports Exerc. 29, 1631–1636.PubMedGoogle Scholar
  34. 34.
    Collomp, K., Candau, R., Lasne, F., Labay, Z., Prefaut, C., and De Ceaurriz, J. (2000), Effects of short-term oral salbutamol administration on exercise endurance and metabolism. J. Appl. Physiol. 89, 430–436.PubMedGoogle Scholar
  35. 35.
    Caruso, J. F., Signorile, J. F., Perry, A. C., et al. (1995), The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med. Sci. Sports Exerc. 27, 1471–1476.PubMedGoogle Scholar
  36. 36.
    Caruso, J. F., Hamill, J. L., and De Garmo, N. (2005), Oral albuterol dosing during the latter stages of a resistance exercise program. J. Strength Cond. Res. 19, 102–107.PubMedCrossRefGoogle Scholar
  37. 37.
    van Baak, M. A., Mayer, L. H., Kempinski, R. E., and Hartgens, F. (2000), Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men. Med. Sci. Sports Exerc. 32, 1300–1306.PubMedCrossRefGoogle Scholar
  38. 38.
    Collomp, K., Le Panse, B., Portier, H., et al. (2005), Effects of acute salbutamol intake during a Wingate test. Int. J. Sports Med. 26, 513–517.PubMedCrossRefGoogle Scholar
  39. 39.
    Ventura, R., Segura, J., Berges, R., et al. (2000), Distinction of inhaled and oral salbutamol by urine analysis using conventional screening procedures for doping control. Ther. Drug Monit. 22, 277–282.PubMedCrossRefGoogle Scholar
  40. 40.
    IOC Medical Commission. (1998), Minutes of meeting Nagano February 1998. Lausanne, Switzerland.Google Scholar
  41. 41.
    Berges, R., Segura, J., Ventura, R., et al. (2000), Discrimination of prohibited oral use of salbutamol from authorized inhaled asthma treatment. Clin. Chem. 46, 1365–1375.PubMedGoogle Scholar
  42. 42. 2006_LIST.pdf, Accessed January 15, 2006.Google Scholar
  43. 43.
    Schweizer, C., Saugy, M., and Kamber, M. (2004), Doping test reveals high concentrations of salbutamol in a Swiss track and field athlete. Clin. J. Sport Med. 14, 312–315.PubMedCrossRefGoogle Scholar
  44. 44.
    Jacobson, G. A., Peterson, G. M., and McLean, S. (1997), Investigation of urinary levels of salbutamol in asthmatic patients receiving inhaled therapy. J. Clin. Pharm. Ther. 22, 119–126.PubMedCrossRefGoogle Scholar
  45. 45.
    Glaxo Smith Kline. (1988), GSK Study GM198/00055/00.Google Scholar

Copyright information

© Humana Press Inc. 2006

Authors and Affiliations

  • Kenneth D. Fitch
    • 1
  1. 1.School of Human Movement and Exercise ScienceUniversity of Western AustraliaNedlandsAustralia

Personalised recommendations